The approval of these advanced therapies has transformed treatment options for atopic dermatitis patients. Dupixent became ...

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, ...

China: A recent analysis from the National Health and Nutrition Examination Survey (NHANES) 2005-2006 revealed that ...

PhD Defense: Effectiveness and safety of dupilumab and JAK-inhibitors in daily practice; Optimizing Treatment for Atopic Dermatitis ...

KKH and the National Skin Centre say there are more such patients, but no recent studies have been done. Read more at ...

Subjects in the trial had a mean baseline EASI score of 27.3 and were either naïve to biologics or had previous treatments ... for treating moderate-to-severe atopic dermatitis (AD), also known as ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch severity in a phase 2b trial, missing all of its endpoints. The ARISE-AD ...

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis. Ahead ...

When 30-year-old Eve (not her real name) gave birth to her baby son, Luke (not his real name), in early 2024, she knew she ...